Mutations in the C9ORF72 gene are the most common cause of amyotrophic lateral sclerosis (ALS). Both toxic gain of function and loss of function pathogenic mechanisms have been proposed. Accruing evidence from mouse knockout studies point to a role for C9ORF72 as a regulator of immune function. To provide further insight into its cellular function, we performed a genome-wide synthetic lethal CRISPR screen in human myeloid cells lacking C9ORF72. We discovered a strong synthetic lethal genetic interaction between C9ORF72 and FIS1, which encodes a mitochondrial membrane protein involved in mitochondrial fission and mitophagy.
One way to study a gene's function is to identify genetic interactors through a synthetic lethal screen. Synthetic lethality occurs when two genetic perturbations, both of which have no effect on cellular viability on their own, cause cell death (Nijman, 2011; Hartman et al., 2001) . The individual loss-of-function is tolerated because the genes are redundant (eg. AKT1 and AKT2) within a single pathway or because they work in parallel pathways and so the other gene can compensate (Nijman, 2011) . A synthetic lethal interaction that comes from the loss of this compensatory mechanism can reveal new insights into gene function. This is a tried and true approach in model organisms like yeast, worms, and flies (Tong et Here we perform a genome-wide synthetic lethal screen with CRISPR-Cas9 in a C9ORF72 knockout human myeloid cell line. We discover a strong genetic interaction between C9ORF72 and FIS1. We find that FIS1 or C9ORF72 deficiency alters the other protein's physical associations with a class of inflammatory regulators. Our results provide further evidence for C9ORF72's role in mediating immune function and identify a potentially parallel role for FIS1 in suppressing excess inflammation.
Results and discussion
Genome-wide CRISPR screen identifies synthetic lethal interaction between FIS1 and
C9ORF72
We generated control and C9ORF72 knockout (C9KO) lines by introducing control or C9ORF72-targeting single-guide RNAs (sgRNAs) in Cas9-expressing human myeloid U937 cells ( Fig. 1A) . We chose this line because previous studies have shown that U937s are highly amenable to genome-wide CRISPR screening and these screens can be performed in an adherent macrophage-like differentiated state with the application of phorbol 12-myristate 13acetate (PMA) (Haney et al., 2018) . Since C9ORF72 is most highly expressed in macrophages and microglia, cells of myeloid origin Zhang et al., 2016) , we reasoned that these differentiated cells could yield the most biologically relevant genetic interactions and indeed, C9ORF72 expression was significantly upregulated after differentiation ( Fig. 1A ).
C9KO cells had no significant defects in cellular growth or macrophage differentiation compared to the control cells ( Fig. 1B-C, Supplementary fig. 1 ). 
Fig. 1 | Genome-wide CRISPR screen for genetic interactors of C9ORF72

FIS1
treated U937 cells, with n=2 replicate screens. Synthetic lethal genetic interactors that passed the 10% FDR in blue.
To perform the genome-wide CRISPR screen, we infected undifferentiated control and C9KO cells with a genome-wide lentiviral library of sgRNAs ( Fig. 1D ). After ten days, we differentiated both populations with 50nM PMA for five days. We then isolated and sequenced the genomic DNA to determine sgRNA abundance in both populations. We used the casTLE analysis tool to determine gene-level effects from relative guide enrichment or depletion in the C9KO population compared to the control populations and to negative control guides (Morgens et al., 2016) . Depletion of multiple sgRNAs for a gene selectively in the C9KO population (denoted by a negative effect score) indicates that loss of both genes impairs growth, suggesting a synthetic lethal interaction.
Using a false discovery rate (FDR) cut-off of 10%, we identified 13 synthetic lethal genetic interactors, with FIS1 as the strongest hit ( Fig. 1E ). As a further filter, we also analyzed our data using a different tool, MAGeCK . FIS1 emerged again as a top hit, while the weaker genes did not (data not shown), prompting us to focus our efforts on FIS1, which encodes a mitochondrial membrane protein with no previously known connection to C9ORF72 
Knockout of FIS1 is synthetic lethal with knockout of C9ORF72 and its binding partners,
SMCR8 and WDR41
To validate the FIS1-C9ORF72 genetic interaction, we generated control, C9KO, FIS1KO, and C9/FIS1KO U937 cells using independent sgRNAs ( Fig. 2A ). While loss of FIS1 or C9ORF72 had no impact on the growth of PMA-treated U937 cells, the FIS1-C9ORF72 double knockout markedly impaired growth and increased apoptosis selectively in differentiated cells ( Fig Intriguingly, in both sets of experiments, we found proteins like BAP31 that were enriched selectively in WT or KO cells, suggesting that the loss of one protein, C9ORF72 or FIS1, can cause the other protein to bind to a different set of partners, perhaps to compensate for the knockout (Fig. 3B, D) . Notably, in all contexts (WT, FIS1KO or C9KO), we identified protein interactors that are ligands for RAGE -the receptor for advanced glycation end products. In WT cells, C9ORF72 bound S100A4 and A6, but in FIS1KO cells, C9ORF72 bound HMGB1/2 To further explore this selective interaction between FIS1 and S100A8/9 in C9KO cells, we measured basal levels of S100A8/9 secretion, since S100A8/9 function extracellularly and intracellularly. Surprisingly, we found reduced S100A8/9 levels in the supernatant of C9KO cells compared to control cells ( Fig. 3F ), suggesting that FIS1 may sequester the S100A8/9
complex within the cell in the absence of C9ORF72. Extracellularly, S100A8/9 can bind to The internal FIS1-S100A8/9 complex and reduced extracellular S100A8/9 signaling in C9KO cells may therefore compensate for the loss of C9ORF72's regulation of inflammation ( In summary, we have harnessed CRISPR screening in human myeloid cells to reveal a novel synthetic lethal interaction between two previously unrelated genes -C9ORF72 and FIS1.
Mass spectrometry and cytokine profiling experiments suggest that FIS1 may have antiinflammatory effects to mitigate the loss of C9ORF72's function in immune regulation.
Materials and methods
Cell culture
U937 cells (ATCC) stably expressing EF1a-Cas9-Blast were a generous gift from the Bassik lab. The cells were cultured in RPMI-1640 medium (Gibco) with 10% heat-inactivated FBS (Gibco), 1% penicillin-streptomycin, and Glutamax (2 mM). HeLa cells (ATCC) stably expressing SFFV-Cas9-BFP were a generous gift from the Bassik lab. BV-2 cells (ATCC) stably expressing EF1a-Cas9-Blast were a generous gift from the Wyss-Coray lab. Both HeLa and BV-2 cells were cultured in DMEM medium (Gibco) with 10% FBS (Gibco), 1% penicillinstreptomycin, and Glutamax (2 mM). To verify Cas9 expression, U937 and BV-2 cells were routinely tested for blasticidin resistance with the application of 10 ug/ml blasticidin. Cells were passaged every 2-3 days in a controlled humidified incubator at 37 °C, with 5% CO2.
For differentiation, U937 cells were resuspended and plated in media containing 50 nM PMA (Sigma-Aldrich), as previously described (Haney et al., 2018) . For screening, ~450 million U937 cells were plated in 300 ml of 50nM PMA-treated U937 growth media in three 15 cm tissue culture dishes. For growth assays, 60,000 cells were plated in 1.5 ml of 50nM PMAtreated media in 24 well plates. After three days, the supernatant was removed and pelleted to isolate any non-adherent cells while the adherent cells were trypsinized. Both cell populations were pooled together and replated in fresh media lacking PMA for two additional days.
Infection of U937 and BV-2 cells was achieved by spinning down 50-100,000 cells with 0.25-1 ml of unconcentrated viral supernatant and 8 ug/ml polybrene for 2 hours at 33 °C. The cells were then resuspended in fresh media. On the third day after infection, cells underwent G418 (750 ug/ml), zeocin (100 ug/ml), or puromycin (1 ug/ml) selection for 3-7 days, after which the antibiotics were removed and the infected populations were allowed to recover and expand.
Cloning of lentiviral constructs
To generate all the knockout lines, guides were cloned into various 3rd generation lentiviral sgRNA expression vectors that were generously gifted from Dr. to be introduced to cells expressing puromycin-resistant guides, the puromycin-resistance cassette was switched out with a G418-resistance cassette.
Lentivirus was produced as described previously (Kramer et al., 2018) . Briefly, HEK293T
(ATCC) cells were cultured under standard conditions (DMEM + 10% FBS + 1% Penicillin-Streptomycin) and used to make lentivirus following standard protocols with 3rd generation packaging plasmids and polyethylenimine. After the first day, fresh media was added to the cells and lentiviral containing media was harvested after 72 hrs and stored at -80 °C.
Incucyte assays
To track growth, cells were placed in the incubator and imaged at 4-12 hr intervals using an Incucyte (Essen) for five days. All cells stably expressed GFP or mCherry from sgRNA constructs so fluorescence was used to track cell number. Cell death was measured by 
RNA-seq
RNA was extracted from U937 cells using the PureLink RNA Mini Kit (Life Technologies) according to the manufacturer's protocol, with on-column PureLink DNase treatment. Total RNA concentration and quality control was determined using the RNA 6000 Nano assay kit (Agilent) on the Agilent 2100 Bioanalyzer System for all samples. mRNA libraries were prepared for Illumina paired-end sequencing using the Agilent SureSelect Strand Specific RNA-Seq Library Preparation kit on the Agilent Bravo Automated Liquid Handling Platform.
Libraries were sequenced on an Illumina HiSeq 4000 sequencer. Alignment of RNAsequencing reads to the transcriptome was performed using STAR with ENCODE standard options, read counts were generated using rsem, and differential expression analysis was performed in R using DESeq2 package . All bioinformatics analyses were performed on Sherlock, a Stanford HPC cluster.
Synthetic lethal screen
The lentiviral genome-wide sgRNA library was produced and infected separately into control and C9KO U937 cells stably expressing EF1a-Cas9-Blast as previously described (Haney et al., 2018) . Control and C9KO infected populations were maintained in separate spinner flasks.
Briefly, ~300 million control cells and ~300 million C9KO cells were infected with the 10 guide/gene genome-wide sgRNA library at a MOI < 1. Infected cells underwent puromycin selection (1ug/mL) for 5 days. Puromycin was then removed and cells were resuspended in normal growth media without puromycin. After selection, sgRNA infection was measured by flow cytometry confirming that > 90% of cells were mCherry+. Sufficient sgRNA library representation was confirmed by Illumina sequencing after selection. Cells were maintained for 10 days at 1000× coverage (~1000 cells containing each sgRNA) at a concentration of 500,000 cells/mL, after which ~450 million control and ~450 million C9KO cells were removed for 50nM PMA differentiation in three 15cm plates as described above. At the end of the 5 day differentiation, genomic DNA was extracted for all screen populations separately according to the protocol included with QIAGEN Blood Maxi Kit. sgRNA sequences were amplified and prepared for deep-sequencing by two sequential PCR reactions as described previously (Morgens et al., 2016) . Final PCR products were sequenced using an Illumina NextSeq.
Guide composition and comparisons across control and C9KO populations were analyzed using casTLE version 1.0 (Morgens et al., 2016) . The enrichment of individual guides was calculated as log ratios between control and C9KO conditions, and gene-level effects were calculated from ten guides targeting each gene. A confidence score was then derived as a loglikelihood ratio describing the significance of the gene-level effect. P-values were then calculated by permutating the targeting guides as previously described (Morgens et al., 2016) .
In parallel, data was analyzed using MAGecK 0.5.7 . Guides were first counted using "mageck count" directly from the sequencing fastq files. We then performed maximumlikelihood analysis of gene essentialities using "mageck mle" with the default parameters and using the library non-targeting guides as parameter for --control-sgrna. Genes predicted as a top hit by both analyses were then selected for further validation.
Immunofluorescence
U937 cells were treated with 50nM PMA as described above. On the third day after trypsinization to remove the PMA, 70-100,000 cells were plated onto glass coverslips in 24well plates with 1ml fresh media. Two days later, cells were washed with 1x PBS and fixed using 4% formaldehyde for 10 minutes. After fixation, cells were washed with 1x PBS, permeabilized with 0.1% Triton X-100, blocked with 5% normal goat serum, and stained with the following antibodies: mouse monoclonal anti-CoxIV (1:1000, Abcam), rabbit polyclonal anti- For data analysis, the collected mass spectra were analyzed using Byonic v3.2.0 (Protein Metrics). Search was performed against the Uniprot Homo Sapiens database at a 12 ppm mass tolerance for both precursor and product ions. Semi specific N-ragged tryptic cleavages were allowed, with up to two missed cleavage sites. Data were validated using the standard reverse-decoy technique at a 1% false discovery rate. Cysteine modified with propionamide was set as a fixed modification in the search. Oxidation on methionine residues, deamidation on asparagine and glutamine, and acetylation on protein N-terminus were set as variable modifications. CRAPome v1.1 analysis (Mellacheruvu et al., 2013) was then used to compute fold change (FC-A) scores from the generated spectral counts and a set of CRAPome controls.
Cytokine assays
Supernatant from PMA-treated U937 cells plated at the same density were collected on the third day of differentiation and spun down at 1000g for 5 minutes and stored at -20 °C until use. Extracellular levels of S100A8/9 were determined from 50 ul of supernatant by the Human S100A8/S100A9 
